Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Investors Really Liked Abbott Labs' Q4 Earnings Results

By Keith Speights - Updated Jan 23, 2020 at 9:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The healthcare giant delivered a solid quarterly performance yet again, with sales growth in all of its segments.

It's fair to say that Abbott Laboratories' (ABT -1.02%) stock performance in 2019 was good but not great. Shares jumped more than 20% last year while lagging well behind the 29% gain delivered by the S&P 500 index. But Abbott is off to a great start in 2020.

The global healthcare leader announced its fourth-quarter results on Wednesday before the market opened. There was a lot for investors to like with its latest quarterly update.

Man in suit touching a dollar sign in a hologram

Image source: Getty Images.

By the numbers

Abbott reported Q4 revenue of $8.3 billion, a solid 7.1% year-over-year increase. This also topped the consensus analysts' estimate of $8.26 billion.

The company announced Q4 diluted earnings per share from continuing operations of $0.59 based on generally accepted accounting principles (GAAP). This reflected a 59.5% jump from the $0.37 per share posted in the year-ago period.

Abbott's adjusted diluted EPS for the fourth quarter came in at $0.95 per share, up from $0.81 in the prior-year period. This met the average analyst earnings estimate.

Behind the numbers

The Q4 sales growth looks even more impressive when adjusted for foreign exchange fluctuations. The company said that its sales increased by 8.5% year over year on a constant-currency basis and excluding the impact of discontinued operations.

All three of Abbott's business segments delivered solid growth. The company's medical devices unit was the biggest winner, with revenue jumping 9.7% year over year to $3.2 billion thanks to double-digit organic sales growth in its diabetes care, electrophysiology, heart failure, and structural heart businesses.

Sales for the company's established pharmaceuticals segment increased 7.8% over the prior-year period to nearly $1.2 billion. Improving performances in Asia and Latin America drove this growth. 

Abbott's nutrition and diagnostics segments trailed with year-over-year revenue growth of 5.2% and 5%, respectively. Total Q4 revenue for the company's diagnostics segment was nearly $2.1 billion, with the Alinity line of diagnostic instruments contributing significantly to growth. The nutrition segment raked in $1.9 billion, with stronger growth in the adult market driven largely by Abbott's Ensure and Glucerna brands.

The company's bottom-line improvement was even better than its sales mainly because operating costs increased at a slower pace than sales did. In addition, Abbott's interest expense and tax expense decreased significantly from the prior-year period.

Looking ahead

Management anticipates full-year 2020 organic sales growth to come in between 7% and 8%, with GAAP EPS between $2.35 and $2.45. Adjusted diluted EPS is expected to be between $3.55 and $3.65. For the first quarter of 2020, the company is anticipating EPS between $0.40 and $0.42, with adjusted EPS between $0.69 and $0.71.

CEO Miles White said that Abbott's focus on organic growth is "driving top-tier performance." He added that the company is "entering 2020 with very good momentum and targeting continued strong growth." 

Abbott remains one of the top blue chip stocks on the market, with solid growth and an attractive dividend. With the potential for Food and Drug Administration clearance of the company's new version of its Freestyle Libre continuous glucose monitoring system in the near future and positive Q4 results under its belt, Abbott has a pretty good chance to deliver an even better performance in 2020 than it did last year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$108.18 (-1.02%) $-1.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.